Health Advisory: Bamlanivimab for Mild/Moderate COVID-19 Patients

Minnesota Department of Health, Mon, Nov 16 15:00 CST 2020

**Action Steps**

*Local and tribal health department*: Please forward to hospitals, clinics, urgent care centers, emergency departments, and convenience clinics in your jurisdiction.

*Hospitals, clinics and other facilities*: Please forward to infection preventionists, infectious disease physicians, emergency department staff, hospitalists, primary care clinicians, and all other health care providers who might see patients with COVID-19.

*Health care providers*:

- Use MDH's Bamlanivimab Screening Tool (see below) to determine if adult or pediatric patients with mild to moderate COVID-19 should be treated with BAM.
- Consider Bamlanivimab for treatment of mild to moderate COVID-19 in adults and pediatric patients who:
  - Have a positive test for SARS-CoV-2 (RT-PCR or antigen),
  - Are within 10 days of the onset of their symptoms,
  - Are at least 12 years of age or older and weigh at least 40 kg (88 lbs), and
  - Who are at high risk for progressing to severe COVID-19 and/or hospitalization.

**Background**

The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on November 9, 2020, to permit the emergency use of the investigational monoclonal antibody therapy Bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients (patients age 12 and more who weigh 40 kg and more) who are at high risk for severe disease due to age or certain medical conditions. The EUA notes that Bamlanivimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.

The US government has secured supplies of this antibody therapy for distribution to states. Shipments are expected weekly beginning today. Getting this therapy to patients is time-sensitive because it must be used as soon as possible after a positive COVID-19 test result and within 10 days of a person showing symptoms. Health care providers are expected to follow the guidance outlined in the EUA to equitably and ethically distribute this treatment. MDH has worked with medical ethicists around the state to develop a framework for this treatment because the demand may be more than the supply.
MDH has posted a Bamlanivimab Screening Tool on the Therapeutic Options for COVID page (https://www.health.state.mn.us/diseases/coronavirus/hcp/therapeutic.html) to assist health care partners in accurately screening positive COVID-19 patients to determine if they are eligible to receive treatment. The eligibility criteria listed in this screening tool are taken from the EUA which lists specific criteria and limitations of authorized use.

If you have a patient that meets the criteria, contact your Regional Health Care Coalition (https://www.health.state.mn.us/communities/ep/coalitions/rhpc.html) to determine where BAM is available in your region. MDH is working on creating a website to assist with location infusion centers.

For More Information

- [Eli Lilly Bamlanivimab for COVID-19 website](https://www.lilly.com/news/media/media-kits/bamlanivimab-covid19)
- [MDH Coronavirus Disease (COVID-19) webpage](https://www.health.state.mn.us/diseases/coronavirus/index.html)
- Call MDH at 651-201-5414 or 877-676-5414.

A copy of this HAN is available at: [MDH Health Alert Network](http://www.health.state.mn.us/han)

The content of this message is intended for public health and health care personnel and response partners who have a need to know the information to perform their duties.